| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.004 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.005 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.091 | 0.006 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.006 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.006 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.093 | 0.007 |